Implicit Bioscience is pleased to announce the commencement of its IC14 COVID-19 clinical trials in the US.
Courier Mail: “Brisbane Covid hope as ‘wonder drug’ trialled in US”
Implicit Bioscience today announced its lead drug IC14 will be tested in a Phase 2 clinical trial in COVID-19 patients in 10 to 15 hospitals across the USA – which commenced this week. The trial, called the COVID-19 and Anti-CD14 Treatment Trial (“CaTT” NCT04391309), is sponsored and funded by the US National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health.
Courier Mail Medical Journalist, Janelle Miles, covered the story on page 4 – and it was widely syndicated via NewsCorp publications in metropolitan and regional areas too.
FDA Awards IC14 as Orphan Drug for MND
The FDA has designated Brisbane biotech Implicit Bioscience’s biologic IC14 an Orphan Drug for the treatment of motor neurone disease.
US Defense Department Funds Program for IC14 in Neurotrauma
The US Department of Defense has funded a USD 735,000 grant entitled “Danger Signalling, Traumatic Brain Injury (TBI), and Epileptogenesis”.
FDA Grants Approval for Heart Attack Trial
The US Food and Drug Administration has issued a “Study May Proceed” letter approving the commencement of clinical study with IC14 in patients with the most severe form of heart attack.
Landmark Publication Points to IC14 Target in ALS-MND
ALS-MND is our leading clinical program in neurodegeneration; however Parkinson’s and Alzheimer’s disease are also coming into sharp focus with some extraordinary new data directly related to IC14.
FDA approves COVID-19 study
On June 3, the US FDA approved an Investigative New Drug (IND) application for IC14 together with remdesivir in 300 COVID-19 patients at risk of acute respiratory distress syndrome (ARDS).
New research links IC14 target to dementia
New research published in the world’s leading journal Neurology reports a link between higher levels of an inflammatory marker called sCD14 and a higher risk of developing dementia.
Australian Immunotherapy Selected for Revolutionary US Clinical Trial Platform Debut
An Australian immunotherapy drug will receive a huge boost when it is tested with four other new concepts across 54 clinical sites across the USA in a search for an effective treatment for ALS (a motor neuron disease).